Cancer Immunotherapy Market Size, Growth, Outlook and Forecast to 2026 | Key Players are F. Hoffmann-La Roche, Ltd; AstraZeneca; Bristol-Myers Squibb Company | Grand View Research, Inc.

November 23 05:12 2021
Cancer Immunotherapy Market Size, Growth, Outlook and Forecast to 2026 | Key Players are F. Hoffmann-La Roche, Ltd; AstraZeneca; Bristol-Myers Squibb Company | Grand View Research, Inc.
“Grand View Research, Inc. – Market Research And Consulting.”
According to a new report published by Grand View Research, rising R&D activities in the cancer immunotherapy field is resulting in the introduction of advanced variants with enhanced efficacy and effectiveness of treatment. Immuno-oncology have shown promising results with improved survival and lower toxicity. A paradigm shift from traditional chemotherapies to immunotherapies is propelling the overall market.

The global cancer immunotherapy market size is likely to reach USD 126.9 billion by 2026, according to a new report by Grand View Research, Inc., exhibiting a CAGR of 9.6% during the forecast period. Increasing patient pool and higher mortality rate are augmenting the need for cancer immunotherapy globally. Furthermore, increasing number of approvals for new immunotherapeutic drugs is driving the global market.

 

Cancer immunotherapy has emerged as a new avenue for revenue generation for pharmaceutical companies. In addition, adverse effects, such as recurrence of cancer and organ failure, associated with conventional chemotherapies and rising demand for technologically advanced healthcare solutions are boosting the demand for immunotherapies. Moreover, introduction of newer drug classes, such as target receptors for multiple myeloma and checkpoint inhibitors, is poised to make way for advanced therapeutics in the market.

 

Introduction of new molecules has been proving to be beneficial for patients who are not responding to chemotherapy. Several new immunotherapeutic options, such as immunomodulators and CAR-T cell therapy, are in the pipeline and are being tested for their ability to provide better cancer treatment.

 

Monoclonal antibodies are the most widely used immunotherapeutic drugs globally. Development of monoclonal antibodies as effective immunotherapeutic options started after the approval of Blincyto (blinatumomab) by Amgen, a bispecific antibody that targets B-cell lymphoblastic leukemia. Increasing R&D pertaining to the use of monoclonal bodies as naked antigen binding antibodies, conjugated, and bispecific antibodies is resulting in discovery of new therapeutic options for cancer treatment.

 

Browse full report with Table of Content @ https://www.grandviewresearch.com/industry-analysis/cancer-immunotherapy-market

 

Cancer Immunotherapy Market Report Highlights

  • Majority of immunotherapy drugs are being used in treatment of cancer of lung, breast, and prostate
  • Monoclonal antibodies emerged as the largest segment because of increasing regulatory approvals and higher efficacy
  • Lung cancer accounted for the largest share in 2018 and will continue to dominate the market through 2025
  • North America was the leading revenue contributor in the market in 2018. Rising incidence of cancer and increasing demand for novel technologies are facilitating the dominance of the region during the forecast period
  • Europe is projected to witness rapid growth during the forecast period owing to rapid adoption of advanced cancer therapeutics for effective treatment
  • Some of the key players are Amgen, Inc.; AstraZeneca; F. Hoffmann La Roche Ltd.; Bayer AG; Bristol-Myers Squibb Company; Eli Lilly and Company; Merck and Co., Inc.; Novartis AG; and Pfizer, Inc.

 

For Requesting a Sample Copy of This Report, Please Visit @ https://www.grandviewresearch.com/industry-analysis/cancer-immunotherapy-market/request/rs1

 

Cancer Immunotherapy Market Segmentation

Grand View Research has segmented the global cancer immunotherapy market based on product, cancer type, and region:

 

Cancer Immunotherapy Product Outlook (Revenue, USD Billion, 2015 – 2026)

  • Monoclonal Antibodies
  • Immunomodulators
  • Oncolytic Viral Therapies and Cancer Vaccines

Cancer Immunotherapy Cancer Type Outlook (Revenue, USD Billion, 2015 – 2026)

  • Lung Cancer
  • Breast Cancer
  • Colorectal Cancer
  • Melanoma
  • Prostate Cancer
  • Head and Neck Cancer
  • Ovarian Cancer
  • Pancreatic Cancer

Cancer Immunotherapy Regional Outlook (Revenue, USD Billion, 2015 – 2026)

  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • France
    • Italy
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Australia
  • Latin America
    • Brazil
    • Mexico
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • U.A.E.

 

Inquire more or share questions if any before the purchase on this report @ https://www.grandviewresearch.com/inquiry/2289/ibb

 

About Grand View Research

 

Grand View Research is a market research and consulting company that offers market research reports, syndicated and customized reports. The company is headquartered in San Francisco, California. It offers client engagement for business consulting and market intelligence from various domains. The clientele is based across various countries with queries coming from more than 50 industries worldwide.

Grand View Research helps its clients to make informed decisions by helping them understand current trends and scenarios. Every year Grand View Research accomplishes more than 300 multi-country market studies to optimize consulting for clients. 

Media Contact
Company Name: Grand View Research, Inc.
Contact Person: Sherry James, Corporate Sales Specialist – U.S.A.
Email: Send Email
Phone: 1888202951
Address:Grand View Research, Inc. 201 Spear Street 1100 San Francisco, CA 94105, United States
City: San Francisco
State: California
Country: United States
Website: https://www.grandviewresearch.com/industry-analysis/cancer-immunotherapy-market

view more articles

About Article Author